After two years characterized by layoffs, pipeline reorganizations, FDA delays and clinical holds, Novavax CEO John Jacobs ...

Novavax shares are trading lower by 9.8% during Monday's session. Shares of vaccine stocks are trading lower after Moderna issued 2025 revenue guidance below analyst estimates.

Novavax's Q3 2024 earnings call and 10-Q reveal a collaboration ... As I write on 01/13/2025 its history of failures to ...

RSV is a contagious pathogen that causes infections ... and advisory board fees from AstraZeneca and Novavax. Segev reports receiving consulting fees from AstraZeneca, CareDx, Moderna Therapeutics ...

The adjuvanted RSV prefusion F protein-based vaccine RSVPreF3 ... from and serving on the advisory boards of AstraZeneca and Novavax; consulting fees from the CDC and the Infectious Diseases ...

The average of price targets set by Wall Street analysts indicates a potential upside of 81.6% in Novavax (NVAX). While the effectiveness of this highly sought-after metric is questionable ...

The company lost more than $3 billion in market value after cutting its forecast for 2025 revenue from its COVID-19 and RSV ...

Novavax (NVAX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

Novavax was up 11%, while BioNTech ADR was up ... their orders before the regulatory approval came in for Moderna’s RSV vaccine. Separately, check out What’s Happening With Aurora Innovation ...

The average of price targets set by Wall Street analysts indicates a potential upside of 81.6% in Novavax (NVAX). While the effectiveness of this highly sought-after metric is questionable, the ...